Uttarakhand News Today

ER+/ HER2-ve Breast Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, G1 Therapeutics, Genetech, Roche, Sanofi, AstraZeneca and Many Others

 Breaking News
  • No posts were found

ER+/ HER2-ve Breast Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, G1 Therapeutics, Genetech, Roche, Sanofi, AstraZeneca and Many Others

June 15
15:37 2021
ER+/ HER2-ve Breast Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, G1 Therapeutics, Genetech, Roche, Sanofi, AstraZeneca and Many Others

HER2-ve Breast Cancer Pipeline

Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. The backbone of their systemic therapy consists of hormonal therapies that block the function of ER through various mechanisms. These include blockade of the receptor itself in breast cancer cells, blockade of the production of its major ligand, estradiol, or degradation of the receptor. However, a subset of ER+/HER2− breast cancers, mostly corresponding to the genomic luminal B genotype, are resistant to hormonal manipulations from the outset of therapies.

DelveInsight’s, “ER+/ HER2-ve Breast Cancer Pipeline Insight, 2021” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ER+/ HER2 -ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

 

ER+/ HER2-ve Breast Cancer Key Players:

  • Eisai
  • G1 Therapeutics
  • Genetech/La Roche
  • Sanofi
  • AstraZeneca
  • And Many Others

 

DelveInsight’s ER+/ HER2-ve Breast Cancer report covers around 5+ products under different phases of clinical development like:

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

 

ER+/ HER2-ve Breast Cancer Therapies:

  • H3B-6545
  • G1T48
  • GDC-9545
  • SAR439859
  • AZD9833
  • And Many Others

 

Current ER+/ HER2-ve Breast Cancer Treatment Scenario and ER+/ HER2-ve Breast Cancer Emerging Therapies:

  • How many companies are developing ER+/ HER2 -ve Breast Cancer drugs?
  • How many ER+/ HER2 -ve Breast Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ER+/ HER2 -ve Breast Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ER+/ HER2 -ve Breast Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for ER+/ HER2 -ve Breast Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

ER+/ HER2 -ve Breast Cancer: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

ER+/ HER2 -ve Breast Cancer – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

ER+/ HER2 -ve Breast Cancer Collaboration Deals

Late Stage Products (Phase III)

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Rintodestrant (G1T48): G1 Therapeutics

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

ER+/ HER2 -ve Breast Cancer Key Companies

ER+/ HER2 -ve Breast Cancer Key Products

ER+/ HER2 -ve Breast Cancer- Unmet Needs

ER+/ HER2 -ve Breast Cancer- Market Drivers and Barriers

ER+/ HER2 -ve Breast Cancer- Future Perspectives and Conclusion

ER+/ HER2 -ve Breast Cancer Analyst Views

ER+/ HER2 -ve Breast Cancer Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight

Related Articles